On August 9, 2022 HCA Healthcare, Inc. (NYSE: HCA), one of the nation’s leading healthcare providers, reported that it will collaborate with Johnson & Johnson to address key healthcare industry issues (Press release, Johnson & Johnson, AUG 9, 2022, View Source [SID1234617964]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The two leading healthcare companies initially will focus on improving health equity, enhancing nursing support, and improving patient outcomes:

HCA Healthcare and Johnson & Johnson will collaborate on a scalable program to improve health outcomes through early-stage lung cancer detection for the Black community. Lung cancer is the number one cause of cancer death among Black patients1, and the two companies will begin to work together on a pilot program in the coming months to increase early identification.
HCA Healthcare, which has more than 93,000 nurses in its system, and Johnson & Johnson have a long-standing commitment to advocating for and supporting nurses. The two healthcare leaders will work together to incorporate Johnson & Johnson’s nursing resources within HCA Healthcare and its affiliate Galen College of Nursing. The companies will work together on health equity issues focused on educational programming, training and other programs that elevate and support nurses with a goal of enriching the nursing experience and skillsets and improving patient outcomes.
HCA Healthcare, through its HCA Healthcare Research Institute, and Johnson & Johnson will collaborate on cardiovascular health initiatives including a retrospective analysis of patients who suffer from heart arrhythmia, as well as research to understand the role digital health technology plays in impacting clinical outcomes for patients with Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD) diseases.
"HCA Healthcare and Johnson & Johnson have had a long and productive relationship, and both companies have worked very hard to address many of our country’s healthcare challenges," said Sam Hazen, chief executive officer of HCA Healthcare. "We believe strongly in the power of strategic partnerships, and we are excited to collaborate to advance health equity, enhance patient care and provide even greater support to our nurses."

"No one company can solve society’s most pressing health challenges alone — it takes collaboration," said Joaquin Duato, chief executive officer of Johnson & Johnson. "That’s why we’re working with HCA Healthcare to improve patient access and outcomes, address the nursing crisis, and advance health equity. We are united in our focus to improve patient care."

HCA Healthcare uses data from more than 35 million annual patient encounters to continually improve care. In addition, with more than 93,000 Registered Nurses (RN), HCA Healthcare is one of the country’s top employers of RNs and invests significantly in nurses and nursing through education and professional development, equipment and technology, resources to promote their physical and emotional wellbeing, and representation at every level of the organization from the bedside to senior leadership.